Walker Maria C 4

What Happened

• Maria C. Walker, a director of MapLight Therapeutics, received equity awards on June 23, 2026: 3,932 restricted stock units (RSUs) and a stock option covering 14,902 shares. Both awards were reported at $0.00 (no cash paid). The grants were made under the Issuer’s 2025 Equity Incentive Plan as part of the company’s non-employee director compensation program.
• The RSUs represent a contingent right to receive one share of common stock per RSU. Both the RSUs and the option vest on the earlier of (i) June 23, 2027, or (ii) the date of the issuer’s next annual stockholder meeting, subject to the director’s continuous service.

Key Details

• Transaction date: 2026-06-23; Form 4 filed: 2026-06-25 (appears timely under the two-business-day Form 4 rule).
• Awards: 3,932 RSUs @ $0.00 (acquired); 14,902-share stock option (reported as derivative) @ $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnotes: RSUs convert 1-for-1 into common shares at vesting (F1, F2); option vests under the same schedule and was granted as director compensation (F3).
• No sale, exercise, or cash transaction was reported; these are grants, not purchases or dispositions.

Context

• RSUs are contingent awards that convert to actual shares only if vesting conditions are met; the option is a grant of the right to acquire shares in the future. Neither represents immediate sale or cash proceeds.
• Director awards are routine compensation and do not necessarily signal insider buying or selling intentions. Purchases (cash buys) are generally more directly informative about insider sentiment than awards.